Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Delphine Quatannens"'
Autor:
Astrid Van den Eynde, Laura Gehrcken, Tias Verhezen, Ho Wa Lau, Christophe Hermans, Hilde Lambrechts, Tal Flieswasser, Delphine Quatannens, Gils Roex, Karen Zwaenepoel, Elly Marcq, Philippe Joye, Edgar Cardenas De La Hoz, Christophe Deben, Alessia Gasparini, Pierre Montay-Gruel, Maxim Le Compte, Eva Lion, Filip Lardon, Steven Van Laere, Vasiliki Siozopoulou, Diana Campillo-Davo, Jorrit De Waele, Patrick Pauwels, Julie Jacobs, Evelien Smits, Jonas R. M. Van Audenaerde
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-19 (2024)
Abstract Background It remains challenging to obtain positive outcomes with chimeric antigen receptor (CAR)-engineered cell therapies in solid malignancies, like colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC). A major obstacle is
Externí odkaz:
https://doaj.org/article/8761eb0063d942beb968b458b3b522ca
Autor:
Abraham Lin, Joey De Backer, Delphine Quatannens, Bart Cuypers, Hanne Verswyvel, Edgar Cardenas De La Hoz, Bart Ribbens, Vasiliki Siozopoulou, Jonas Van Audenaerde, Elly Marcq, Filip Lardon, Kris Laukens, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts
Publikováno v:
Bioengineering & Translational Medicine, Vol 7, Iss 3, Pp n/a-n/a (2022)
Abstract Melanoma remains a deadly cancer despite significant advances in immune checkpoint blockade and targeted therapies. The incidence of melanoma is also growing worldwide, which highlights the need for novel treatment options and strategic comb
Externí odkaz:
https://doaj.org/article/17eb6880cebd4836b899d3e52353311c
Autor:
Patrick Pauwels, Marc Peeters, Jonas Van Audenaerde, Elly Marcq, Bianca von Scheidt, Ashleigh Davey, Amanda Oliver, Jorrit De Waele, Delphine Quatannens, Jinthe Van Loenhout, Geert Roeyen, Filip Lardon, Clare Slaney, Evelien Smits
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/f32c05db09ba4ce4b51ec7d16d56ee53
Autor:
Jonas RM Van Audenaerde, Elly Marcq, Bianca vonScheidt, Ashleigh S Davey, Amanda J Oliver, Jorrit De Waele, Delphine Quatannens, Jinthe Van Loenhout, Patrick Pauwels, Geert Roeyen, Filip Lardon, Clare Y Slaney, Marc Peeters, Michael H Kershaw, Phillip K Darcy, Evelien LJM Smits
Publikováno v:
Clinical & Translational Immunology, Vol 9, Iss 8, Pp n/a-n/a (2020)
Abstract Objectives With the poorest 5‐year survival of all cancers, improving treatment for pancreatic cancer is one of the biggest challenges in cancer research. We sought to explore the potential of combining both priming and activation of the i
Externí odkaz:
https://doaj.org/article/b9d446da1e9b4c0f9e0a3b2ed6c08998
Autor:
Jinthe Van Loenhout, Laurie Freire Boullosa, Delphine Quatannens, Jorrit De Waele, Céline Merlin, Hilde Lambrechts, Ho Wa Lau, Christophe Hermans, Abraham Lin, Filip Lardon, Marc Peeters, Annemie Bogaerts, Evelien Smits, Christophe Deben
Publikováno v:
Cells, Vol 10, Iss 11, p 2936 (2021)
Targeting the redox balance of malignant cells via the delivery of high oxidative stress unlocks a potential therapeutic strategy against glioblastoma (GBM). We investigated a novel reactive oxygen species (ROS)-inducing combination treatment strateg
Externí odkaz:
https://doaj.org/article/fb742ef891dc479883b58c28c9e1e561
Autor:
Christophe Deben, Jinthe Van Loenhout, Ho Wa Lau, Annemie Bogaerts, Marc Peeters, Abraham Lin, Christophe Hermans, Delphine Quatannens, Evelien Smits, Jorrit De Waele, Laurie Freire Boullosa, Hilde A. J. Lambrechts, Céline Merlin, Filip Lardon
Publikováno v:
Cells
Volume 10
Issue 11
Cells, Vol 10, Iss 2936, p 2936 (2021)
Volume 10
Issue 11
Cells, Vol 10, Iss 2936, p 2936 (2021)
Targeting the redox balance of malignant cells via the delivery of high oxidative stress unlocks a potential therapeutic strategy against glioblastoma (GBM). We investigated a novel reactive oxygen species (ROS)-inducing combination treatment strateg
Autor:
Delphine Quatannens, Yannick Verhoeven, Peter Van Dam, Filip Lardon, Hans Prenen, Geert Roeyen, Marc Peeters, Evelien L.J. Smits, Jonas Van Audenaerde
Publikováno v:
Pharmacology and therapeutics
Pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer related death. The urgent need for effective therapies is highlighted by the lack of adequate targeting. In PDAC, hedgehog (Hh) signaling is known to be aberrantly activated, w
Autor:
Jorrit De Waele, An Wouters, Evelien Smits, Filip Lardon, Yannick Verhoeven, Peter van Dam, Delphine Quatannens, Xuan Bich Trinh
Publikováno v:
International Journal of Molecular Sciences
International journal of molecular sciences
International Journal of Molecular Sciences, Vol 22, Iss 1807, p 1807 (2021)
International journal of molecular sciences
International Journal of Molecular Sciences, Vol 22, Iss 1807, p 1807 (2021)
Even though cervical cancer is partly preventable, it still poses a great public health problem throughout the world. Current therapies have vastly improved the clinical outcomes of cervical cancer patients, but progress in new systemic treatment mod
Autor:
Jonas Van Audenaerde, Andreas Domen, Christophe Deben, Marc Peeters, Evelien Smits, Timon Vandamme, Filip Lardon, Hans Prenen, Yannick Verhoeven, Annelies Janssens, Peter van Dam, Delphine Quatannens, An Wouters, Sara Zanivan, Geert Roeyen
Publikováno v:
Cancers, Vol 13, Iss 987, p 987 (2021)
Cancers
Cancers
Simple Summary The tumor microenvironment (TME) is increasingly believed to be involved in therapy resistance and disease progression of different cancer types. Cancer-associated fibroblasts (CAFs) are prominent components and a central player in cre
Autor:
Bianca von Scheidt, Clare Y Slaney, Geert Roeyen, Michael H. Kershaw, Jorrit De Waele, Delphine Quatannens, Marc Peeters, Amanda J Oliver, Phillip K. Darcy, Elly Marcq, Filip Lardon, Jinthe Van Loenhout, Patrick Pauwels, Ashleigh S Davey, Jonas Van Audenaerde, Evelien Smits
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background With the poorest 5-year survival of all cancers, improving treatment for pancreatic cancer is one of the biggest challenges in cancer research. In this era of combination immunotherapies, we sought to explore the potential of combining bot